Hi-Tech Pharmacal (NASDAQ:HITK) is one of today's notable stocks in decline, down 1.9% to $34.69. The Dow Jones Industrial Average is now trading 0.4% lower to 13,089 and the S&P is trading 0.6% lower to 1,418.
In the past 52 weeks, Hi-Tech Pharmacal share prices have been bracketed by a low of $18.68 and a high of $44.58 and are now at $34.69, 86% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.2% while the 200-day MA has slid 0.2%.
Hi-Tech Pharmacal (NASDAQ:HITK) has potential upside of 11.0% based on a current price of $34.69 and analysts' consensus price target of $38.50. The stock should discover initial support at its 50-day moving average (MA) of $33.07 and subsequent support at its 200-day MA of $32.94.
Hi-Tech Pharmacal Co., Inc. manufactures prescription and over-the-counter generic and branded pharmaceuticals in liquid and semi-solid dosage forms. The Company also manufactures sterile ophthalmic, otic, and inhalation products and provides sterile manufacturing contract services. Hi-Tech markets its own products under names such as H-T, Rx Choice, DiabetiDerm, and Steri-Optics.